Companies › AskBio
4 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 2; Neurology, Cardiovascular, Metabolic and endocrine; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AAV2-GDNF Adeno-associated virus serotype 2 delivering glial cell line-derived neurotrophic factor ( | GDNF | Phase 2 | Parkinson Disease | Aug 2028 |
| AB-1002 Protein phosphatase 1 catalytic subunit beta (PP1β) inhibitor delivered via intracoronary | PPP1CB | Phase 2 | Congestive Heart Failure | Dec 2030 |
| AB-1009 GAA gene therapy delivered via recombinant adeno-associated virus (AAV) | GAA | Phase 1 | Pompe Disease (Late-onset) | Sep 2028 |
| AB-1003 Gene therapy delivering functional FKRP gene | FKRP | Phase 1 | Limb Girdle Muscular Dystrophy | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06285643 | AAV2-GDNF | Phase 2 | Parkinson Disease | Neurology | Aug 2028 |
| NCT07282847 | AB-1009 | Phase 1 | Pompe Disease (Late-onset) | Metabolic and endocrine | Sep 2028 |
| NCT05230459 | AB-1003 | Phase 1 | Limb Girdle Muscular Dystrophy | Neurology | Dec 2028 |
| NCT05598333 | AB-1002 | Phase 2 | Congestive Heart Failure | Cardiovascular | Dec 2030 |
ML Bio Solutions Atamyo Therapeutics Brain Neurotherapy Bio Astellas GeneCradle Amicus Therapeutics Sanofi Spark Therapeutics
Elpida Therapeutics SPC MED Institute Neurogene Nippon Shinyaku REGENXBIO
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.